RecruitingPhase 3NCT03925662
Mebendazole as Adjuvant Treatment for Colon Cancer
Clinical Study Evaluating Mebendazole as Adjuvant Therapy in Patients With Colorectal Cancer
Sponsor
Sherief Abd-Elsalam
Enrollment
40 participants
Start Date
Apr 1, 2019
Study Type
INTERVENTIONAL
Conditions
Summary
mebendazole treating colon cancer
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is testing whether mebendazole — an inexpensive antiparasitic medication widely used to treat intestinal worms — can also help slow the growth of stage 4 colorectal cancer when added to standard treatment.
**You may be eligible if...**
- You have stage 4 colorectal cancer (cancer that has spread to other organs)
- You are able to provide informed consent
**You may NOT be eligible if...**
- You have agranulocytosis (a severe condition where white blood cell counts are dangerously low)
- You are pregnant
- You have a known allergy to mebendazole
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGFolfox with avastin
Folfox with avastin only
DRUGMebendazole
Folfox with avastin with mebendazole
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03925662
Related Trials
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
NCT052868141 location
Evaluation for NCI Surgery Branch Clinical Research Protocols
NCT000018231 location
Epidemiological and Molecular Colorectal Cancer Registry
NCT027813371 location
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
NCT0442182018 locations
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
NCT0630524712 locations